Our Blog

Welcome to the CERES Regulatory Services blog! Here, you’ll find a wide range of articles and resources on Accelerated Approval Pathways and FDA Fast Track Designation, FDA Breakthrough Therapy Designation, FDA Priority Review Designation, FDA Approval Process, Regulatory Strategy for Therapeutics (Drugs, Biologics, Vaccines, Medical Devices, Cell and Gene Therapy and Advanced Tissue Products), Nonclinical Development, Clinical Development, FDA Meetings, Drug Development Pathways, Expedited Drug Approval, Innovative Therapies Development, NDA and BLA Submission Strategies, FDA Regulatory Guidance, FDA Accelerated and Expedited programs and Strategies of Interest to the Regulatory Scientist.

The Ervebo Resubmission Journey: From FDA CRL to Approval 

Categories: Clinical Studies
84

Hello Regulatory Scientists, 

Today, let’s delve into the journey of Ervebo (Ebola Zaire Vaccine, live) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. 

Regulatory History and Initial Submission 

Drug: Ervebo (Ebola Zaire Vaccine, live) 
Mechanism of Action: Live attenuated vaccine designed to provoke an immune response against the Ebola virus 
Indication: Prevention of disease caused by the Ebola virus (Zaire ebolavirus) 
Initial Submission Date: June 2019 

The Complete Response Letter (CRL) 

CRL Date: October 2019 
CRL Concerns: 

  1. Manufacturing Process: The FDA raised concerns about the quality and consistency of the manufacturing process. 
  1. Stability Data: Request for additional stability data to ensure the vaccine’s efficacy over its shelf life. 
  1. Labeling and Risk Management: Need for detailed labeling and a robust risk management plan to monitor and mitigate potential adverse effects. 

Resubmission Strategy 

Merck, the company behind Ervebo, implemented a comprehensive strategy to address the FDA’s concerns: 

  1. Manufacturing Process Improvements: Made significant enhancements to the manufacturing process to ensure consistency and quality. 
  1. Stability Data Collection: Conducted additional studies to gather more robust stability data to support the vaccine’s efficacy over its intended shelf life. 
  1. Labeling and Risk Management Plan: Developed detailed labeling and a robust risk management plan, including monitoring guidelines and patient education materials. 
  1. Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions. 

Resubmission Date: December 2019 

Outcome 

Approval Date: December 2019 
Ervebo was approved for the prevention of disease caused by the Ebola virus (Zaire ebolavirus), providing a critical tool in the fight against Ebola outbreaks. 

Lessons Learned 

The journey of Ervebo from CRL to approval highlights several key lessons for drug developers: 

  1. Manufacturing Process Enhancements: Ensuring the quality and consistency of the manufacturing process is crucial. Proactive improvements and rigorous quality control measures can prevent setbacks. 
  1. Comprehensive Data Collection: Providing extensive stability data to support the efficacy of the vaccine over its shelf life is essential to addressing FDA concerns. 
  1. Effective Labeling and Risk Management: Developing and implementing detailed labeling and a robust risk management plan can help mitigate potential adverse effects and ensure patient safety. 
  1. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations. 
  1. Proactive Quality Control: Implementing stringent quality control measures ensures the consistency and reliability of the vaccine’s production. 

Relevance for Current Drug Developers 

For companies developing drugs today, the Ervebo case underscores the importance of strategic planning and meticulous attention to detail in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval: 

  1. Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including manufacturing processes and stability data, meet FDA standards. 
  1. Proactive Risk Management: Identify and address potential risks early in the development process to prevent issues from arising during FDA review. 
  1. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process. 
  1. Invest in Quality Data: Prioritize the collection of high-quality, detailed safety and efficacy data to support the submission. 
  1. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns, even if formal hearings are not required. 

By learning from the Ervebo resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval. 

Stay diligent and strategic, 

CERES Regulatory Services 

Picture of Asad Khan
Asad Khan